Recently, both sides of the Atlantic have seen developments in paediatric regulation. In Europe, the EMA has published a new template for the paediatric investigation plan (PIP), which should help dispel some (but by no means all) doubts and inconsistencies regarding the PIP document. In the USA, the Food and Drug Administration Safety and Innovations Act (FDASIA) has effectively made it mandatory to submit a paediatric study plan (PSP, the US equivalent of a PIP) soon after completion of phase II of development. Drug companies will need to work out how best to manage having two approved plans in parallel and avoid discrepancies.
You must be a member of EMWA in order to download the full article.
EMWA members please log in to download the full article.
If you would like to become a member of EMWA, please join here.
Deputy Managing Editor
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Medical Communications/Writing for Patients
My First Medical Writing
News from the EMA
Out on Our Own
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Lay out Designer